Table of Contents Author Guidelines Submit a Manuscript
Journal of Nucleic Acids
Volume 2012, Article ID 687359, 19 pages
http://dx.doi.org/10.1155/2012/687359
Review Article

p53 Family: Role of Protein Isoforms in Human Cancer

Department of Surgery and Cancer Biology, Vanderbilt University Medical Center, 1255 Light Hall, 2215 Garland Avenue, Nashville, TN 37232, USA

Received 29 April 2011; Accepted 4 July 2011

Academic Editor: Didier Auboeuf

Copyright © 2012 Jinxiong Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. T. Wang, R. Sandberg, S. Luo et al., “Alternative isoform regulation in human tissue transcriptomes,” Nature, vol. 456, no. 7221, pp. 470–476, 2008. View at Google Scholar
  2. Q. Pan, Q. Shai, L. J. Lee, B. J. Frey, and B. J. Blencowe, “Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing,” Nature Genetics, vol. 40, no. 12, pp. 1413–1415, 2008. View at Google Scholar
  3. R. Klinck, A. Bramard, L. Inkel et al., “Multiple alternative splicing markers for ovarian cancer,” Cancer Research, vol. 68, no. 3, pp. 657–663, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. P. Venables, R. Klinck, C. Koh et al., “Cancer-associated regulation of alternative splicing,” Nature Structural and Molecular Biology, vol. 16, no. 6, pp. 670–676, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. C. Bourdon, K. Fernandes, F. Murray-Zmijewski et al., “p53 isoforms can regulate p53 transcriptional activity,” Genes and Development, vol. 19, no. 18, pp. 2122–2137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Dötsch, F. Bernassola, D. Coutandin, E. Candi, and G. Melino, “p63 and p73, the ancestors of p53,” Cold Spring Harbor perspectives in biology, vol. 2, no. 9, p. a004887, 2010. View at Google Scholar
  7. R. Rutkowski, K. Hofmann, and A. Gartner, “Phylogeny and function of the invertebrate p53 superfamily,” Cold Spring Harbor Perspectives in Biology, vol. 2, no. 7, Article ID a001131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Petre-Lazar, G. Livera, S. G. Moreno et al., “The role of p63 in germ cell apoptosis in the developing testis,” Journal of Cellular Physiology, vol. 210, no. 1, pp. 87–98, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Kaghad, H. Bonnet, A. Yang et al., “Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers,” Cell, vol. 90, no. 4, pp. 809–819, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Yang, M. Kaghad, Y. Wang et al., “p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities,” Molecular Cell, vol. 2, no. 3, pp. 305–316, 1998. View at Google Scholar · View at Scopus
  11. G. Melino, X. Lu, M. Gasco, T. Crook, and R. A. Knight, “Functional regulation of p73 and p63: development and cancer,” Trends in Biochemical Sciences, vol. 28, no. 12, pp. 663–670, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. D. P. Lane and L. V. Crawford, “T antigen is bound to a host protein in SV40 transformed cells,” Nature, vol. 278, no. 5701, pp. 261–263, 1979. View at Google Scholar · View at Scopus
  13. D. I. H. Linzer and A. J. Levine, “Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells,” Cell, vol. 17, no. 1, pp. 43–52, 1979. View at Google Scholar · View at Scopus
  14. A. E. Sayan, M. Rossi, G. Melino, and R. A. Knight, “p73: in silico evidence for a putative third promoter region,” Biochemical and Biophysical Research Communications, vol. 313, no. 3, pp. 765–770, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. A. E. Vilgelm, M. K. Washington, J. Wei, H. Chen, V. S. Prassolov, and A. I. Zaika, “Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors,” Molecular Cancer Therapeutics, vol. 9, no. 3, pp. 693–705, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Yang and F. McKeon, “p63 and p73: p53 mimics, menaces and more,” Nature Reviews Molecular Cell Biology, vol. 1, no. 3, pp. 199–207, 2000. View at Google Scholar · View at Scopus
  17. T. Stiewe, C. C. Theseling, and B. M. Pützer, “Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA binding. Implications for tumorigenesis,” Journal of Biological Chemistry, vol. 277, no. 16, pp. 14177–14185, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Ishimoto, C. Kawahara, K. Enjo, M. Obinata, T. Nukiwa, and S. Ikawa, “Possible oncogenic potential of ΔNp73: a newly identified isoform of human p73,” Cancer Research, vol. 62, no. 3, pp. 636–641, 2002. View at Google Scholar · View at Scopus
  19. Y. Yin, C. W. Stephen, M. G. Luciani, and R. Fåhraeus, “p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products,” Nature Cell Biology, vol. 4, no. 6, pp. 462–467, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Courtois, G. Verhaegh, S. North et al., “ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53,” Oncogene, vol. 21, no. 44, pp. 6722–6728, 2002. View at Google Scholar · View at Scopus
  21. V. Marcel, S. Perrier, M. Aoubala et al., “Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript,” FEBS Letters, vol. 584, no. 21, pp. 4463–4468, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Zaika, M. Irwin, C. Sansome, and U. M. Moll, “Oncogenes induce and activate endogenous p73 protein,” Journal of Biological Chemistry, vol. 276, no. 14, pp. 11310–11316, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. A. I. Zaika, S. Kovalev, N. D. Marchenko, and U. M. Moll, “Overexpression of the wild type p73 gene in breast cancer tissues and cell lines,” Cancer Research, vol. 59, no. 13, pp. 3257–3263, 1999. View at Google Scholar · View at Scopus
  24. V. de Laurenzi, M. V. Catani, A. Terrinoni et al., “Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ,” Cell Death and Differentiation, vol. 6, no. 5, pp. 389–390, 1999. View at Google Scholar
  25. Y. Ueda, M. Hijikata, S. Takagi, T. Chiba, and K. Shimotohno, “New p73 variants with altered C-terminal structures have varied transcriptional activities,” Oncogene, vol. 18, no. 35, pp. 4993–4998, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Vanbokhoven, G. Melino, E. Candi, and W. Declercq, “p63, a story of mice and men,” Journal of Investigative Dermatology, vol. 131, no. 6, pp. 1196–1207, 2011. View at Publisher · View at Google Scholar
  27. M. Mangiulli, A. Valletti, M. F. Caratozzolo et al., “Identification and functional characterization of two new transcriptional variants of the human p63 gene,” Nucleic Acids Research, vol. 37, no. 18, pp. 6092–6104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Hofstetter, A. Berger, H. Fiegl et al., “Alternative splicing of p53 and p73: the novel p53 splice variant p53 is an independent prognostic marker in ovarian cancer,” Oncogene, vol. 29, no. 13, pp. 1997–2004, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Dohn, S. Zhang, and X. Chen, “p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes,” Oncogene, vol. 20, no. 25, pp. 3193–3205, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Tomkova, A. Belkhiri, W. El-Rifai, and A. I. Zaika, “p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells,” Cancer Research, vol. 64, no. 18, pp. 6390–6393, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Sauer, A. C. Bretz, R. Beinoraviciute-Kellner et al., “C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity,” Nucleic Acids Research, vol. 36, no. 6, pp. 1900–1912, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Graupner, K. Schulze-Osthoff, F. Essmann, and R. U. Jänicke, “Functional characterization of p53β and p53γ, two isoforms of the tumor suppressor p53,” Cell Cycle, vol. 8, no. 8, pp. 1238–1248, 2009. View at Google Scholar · View at Scopus
  33. K. A. Avery-Kiejda, D. Z. Xu, L. J. Adams et al., “Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin,” Clinical Cancer Research, vol. 14, no. 6, pp. 1659–1668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Nakagawa, M. Takahashi, T. Ozaki et al., “Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter,” Molecular and Cellular Biology, vol. 22, no. 8, pp. 2575–2585, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. A. I. Zaika, N. Slade, S. H. Erster et al., “δNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors,” Journal of Experimental Medicine, vol. 196, no. 6, pp. 765–780, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. H. C. Moore, L. B. Jordan, S. E. Bray et al., “The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer,” Oncogene, vol. 29, no. 49, pp. 6475–6484, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Marcel, V. Vijayakumar, L. Fernández-Cuesta et al., “P53 regulates the transcription of its Δ133p53 isoform through specific response elements contained within the TP53 P2 internal promoter,” Oncogene, vol. 29, no. 18, pp. 2691–2700, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Aoubala, F. Murray-Zmijewski, M. P. Khoury et al., “p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage,” Cell Death and Differentiation, vol. 18, no. 2, pp. 248–258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. T. J. Grob, U. Novak, C. Maisse et al., “Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53,” Cell Death and Differentiation, vol. 8, no. 12, pp. 1213–1223, 2001. View at Publisher · View at Google Scholar
  40. D. A. Arvanitis, E. Lianos, N. Soulitzis, D. Delakas, and D. A. Spandidos, “Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer,” Oncology Reports, vol. 12, no. 5, pp. 1131–1137, 2004. View at Google Scholar · View at Scopus
  41. R. Malaguarnera, V. Vella, R. Vigneri, and F. Frasca, “p53 family proteins in thyroid cancer,” Endocrine-Related Cancer, vol. 14, no. 1, pp. 43–60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. M. L. Iacono, V. Monica, S. Saviozzi et al., “p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue,” Journal of Thoracic Oncology, vol. 6, no. 3, pp. 473–481, 2011. View at Publisher · View at Google Scholar
  43. T. L. Slatter, N. Hung, H. Campbell et al., “Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform,” Blood, vol. 117, no. 19, pp. 5166–5177, 2011. View at Publisher · View at Google Scholar
  44. B. Maier, W. Gluba, B. Bernier et al., “Modulation of mammalian life span by the short isoform of p53,” Genes and Development, vol. 18, no. 3, pp. 306–319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Pehar, K. J. O'Riordan, M. Burns-Cusato et al., “Altered longevity-assurance activity of p53 : p44 in the mouse causes memory loss, neurodegeneration and premature death,” Aging Cell, vol. 9, no. 2, pp. 174–190, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Ungewitter and H. Scrable, “Δ40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs,” Genes and Development, vol. 24, no. 21, pp. 2408–2419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. W. Song, S. W. Huo, J. J. Lü et al., “Expression of p53 isoforms in renal cell carcinoma,” Chinese Medical Journal, vol. 122, no. 8, pp. 921–926, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Fujita, A. M. Mondal, I. Horikawa et al., “p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence,” Nature Cell Biology, vol. 11, no. 9, pp. 1135–1142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Boldrup, J. C. Bourdon, P. J. Coates, B. Sjöström, and K. Nylander, “Expression of p53 isoforms in squamous cell carcinoma of the head and neck,” European Journal of Cancer, vol. 43, no. 3, pp. 617–623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. J.-C. Bourdon, M. P. Khoury, A. Diot et al., “p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients,” Breast Cancer Research, vol. 13, no. 1, article R7, 2011. View at Publisher · View at Google Scholar
  51. C. B. Dugani, A. Paquin, M. Fujitani, D. R. Kaplan, and F. D. Miller, “p63 antagonizes p53 to promote the survival of embryonic neural precursor cells,” Journal of Neuroscience, vol. 29, no. 20, pp. 6710–6721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. D. I. Schwartz, N. M. Lindor, C. Walsh-Vockley et al., “p73 mutations are not detected in sporadic and hereditary breast cancer,” Breast Cancer Research and Treatment, vol. 58, no. 1, pp. 25–29, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Kovalev, N. Marchenko, S. Swendeman, M. LaQuaglia, and U. M. Moll, “Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines,” Cell Growth and Differentiation, vol. 9, no. 11, pp. 897–903, 1998. View at Google Scholar · View at Scopus
  54. M. Mai, H. Huang, C. Reed et al., “Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions,” Genomics, vol. 51, no. 3, pp. 359–363, 1998. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Yokomizo, M. Mai, D. J. Tindall et al., “Overexpression of the wild type p73 gene in human bladder cancer,” Oncogene, vol. 18, no. 8, pp. 1629–1633, 1999. View at Google Scholar · View at Scopus
  56. Y. Nimura, M. Mihara, S. Ichimiya et al., “p73, a gene related to p53, is not mutated in esophageal carcinomas,” International Journal of Cancer, vol. 78, no. 4, pp. 437–440, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Yang, N. Walker, R. Bronson et al., “p73-Deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours,” Nature, vol. 404, no. 6773, pp. 99–103, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Tomasini, K. Tsuchihara, M. Wilhelm et al., “TAp73 knockout shows genomic instability with infertility and tumor suppressor functions,” Genes and Development, vol. 22, no. 19, pp. 2677–2691, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. M. T. Wilhelm, A. Rufini, M. K. Wetzel et al., “Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway,” Genes and Development, vol. 24, no. 6, pp. 549–560, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Tannapfel, K. John, N. Miše et al., “Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73,” Carcinogenesis, vol. 29, no. 1, pp. 211–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Stiewe, S. Tuve, M. Peter, A. Tannapfel, A. H. Elmaagacli, and B. M. Pützer, “Quantitative TP73 transcript analysis in hepatocellular carcinomas,” Clinical Cancer Research, vol. 10, no. 2, pp. 626–633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Domínguez, J. M. García, C. Peña et al., “ΔTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1,” Journal of Clinical Oncology, vol. 24, no. 5, pp. 805–815, 2006. View at Publisher · View at Google Scholar
  63. I. Fillippovich, N. Sorokina, M. Gatei et al., “Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53,” Oncogene, vol. 20, no. 4, pp. 514–522, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Concin, K. Becker, N. Slade et al., “Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo,” Cancer Research, vol. 64, no. 7, pp. 2449–2460, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Castillo, S. Goñi, M. U. Latasa et al., “Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform ΔEx2p73 in human hepatocellular tumors,” Gastroenterology, vol. 137, no. 5, pp. 1805–1815, article e4, 2009. View at Publisher · View at Google Scholar
  66. S. W. Ng, G. K. Yiu, Y. Liu et al., “Analysis of p73 in human borderline and invasive ovarian tumor,” Oncogene, vol. 19, no. 15, pp. 1885–1890, 2000. View at Google Scholar · View at Scopus
  67. J. O'Nions, L. A. Brooks, A. Sullivan et al., “p73 is over-expressed in vulval cancer principally as the δ2 isoform,” British Journal of Cancer, vol. 85, no. 10, pp. 1551–1556, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Tuve, S. N. Wagner, B. Schitrek, and B. M. Pützer, “Alterations of ΔTA-p73 splice transcripts during melanoma development and progression,” International Journal of Cancer, vol. 108, no. 1, pp. 162–166, 2004. View at Publisher · View at Google Scholar
  69. T. Shishikura, S. Ichimiya, T. Ozaki et al., “Mutational analysis of the p73 gene in human breast cancers,” International Journal of Cancer, vol. 84, no. 3, pp. 321–325, 1999. View at Publisher · View at Google Scholar · View at Scopus
  70. M. M. Koker and C. G. Kleer, “p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma,” American Journal of Surgical Pathology, vol. 28, no. 11, pp. 1506–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Ribeiro-Silva, L. N. Z. Ramalho, S. B. Garcia, and S. Zucoloto, “Does the correlation between EBNA-1 and p63 expression in breast carcinomas provide a clue to tumorigenesis in Epstein-Barr virus-related breast malignancies?” Brazilian Journal of Medical and Biological Research, vol. 37, no. 1, pp. 89–95, 2004. View at Google Scholar · View at Scopus
  72. L. Hanker, T. Karn, E. Ruckhaeberle et al., “Clinical relevance of the putative stem cell marker p63 in breast cancer,” Breast Cancer Research and Treatment, vol. 122, no. 3, pp. 765–775, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Tokuchi, T. Hashimoto, Y. Kobayashi et al., “The expression of p73 is increased in lung cancer, independent of p53 gene alteration,” British Journal of Cancer, vol. 80, no. 10, pp. 1623–1629, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Uramoto, K. Sugio, T. Oyama et al., “Expression of ΔNp73 predicts poor prognosis in lung cancer,” Clinical Cancer Research, vol. 10, no. 20, pp. 6905–6911, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Di Vinci, F. Sessa, I. Casciano et al., “Different intracellular compartmentalization of TA and ΔNp73 in non-small cell lung cancer,” International Journal of Oncology, vol. 34, no. 2, pp. 449–456, 2009. View at Publisher · View at Google Scholar
  76. A. Daskalos, S. Logotheti, S. Markopoulou et al., “Global DNA hypomethylation-induced ΔNp73 transcriptional activation in non-small cell lung cancer,” Cancer Letters, vol. 300, no. 1, pp. 79–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Pelosi, F. Pasini, C. O. Stenholm et al., “p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?” Journal of Pathology, vol. 198, no. 1, pp. 100–109, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. P. P. Massion, P. M. Taflan, S. M. J. Rahman et al., “Significance of p63 amplification and overexpression in lung cancer development and prognosis,” Cancer Research, vol. 63, no. 21, pp. 7113–7121, 2003. View at Google Scholar · View at Scopus
  79. F. Chen, H. Chen, H. Tao, Y. Zhang, B. Ye, and M. Liu, “Different expressions of p53 gene family members and their clinical significance in human non-small cell lung cancer,” Zhongguo Fei Ai Za Zhi, vol. 7, no. 4, pp. 339–343, 2004. View at Google Scholar · View at Scopus
  80. T. Iwata, H. Uramoto, K. Sugio et al., “A lack of prognostic significance regarding ΔNp63 immunoreactivity in lung cancer,” Lung Cancer, vol. 50, no. 1, pp. 67–73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Narahashi, T. Niki, T. Wang et al., “Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma,” Histopathology, vol. 49, no. 4, pp. 349–357, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Yokomizo, M. Mai, D. G. Bostwick et al., “Mutation and expression analysis of the p73 gene in prostate cancer,” Prostate, vol. 39, no. 2, pp. 94–100, 1999. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Guan and Y. Chen, “Aberrant expression of ΔNp73 in benign and malignant tumours of the prostate: correlation with Gleason score,” Journal of Clinical Pathology, vol. 58, no. 11, pp. 1175–1179, 2005. View at Publisher · View at Google Scholar
  84. J. K. Parsons, E. A. Saria, M. Nakayama et al., “Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells,” Prostate, vol. 69, no. 5, pp. 559–569, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. P. K. Dhillon, M. Barry, M. J. Stampfer et al., “Aberrant cytoplasmic expression of p63 and prostate cancer mortality,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 2, pp. 595–600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Guan, H. X. Peng, B. Yu, and Y. Lu, “p73 overexpression and angiogenesis in human colorectal carcinoma,” Japanese Journal of Clinical Oncology, vol. 33, no. 5, pp. 215–220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. F. P. Carneiro, L. N. Z. Ramalho, S. Britto-Garcia, A. Ribeiro-Silva, and S. Zucoloto, “Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas,” Diseases of the Colon and Rectum, vol. 49, no. 5, pp. 588–594, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. S. G. Chi, S. G. Chang, S. J. Lee, C. H. Lee, J. I. Kim, and J. H. Park, “Elevated and biallelic expression of p73 is associated with progression of human bladder cancer,” Cancer Research, vol. 59, no. 12, pp. 2791–2793, 1999. View at Google Scholar · View at Scopus
  89. P. Puig, P. Capodieci, M. Drobnjak et al., “p73 Expression in human normal and tumor tissues: loss of p73α expression is associated with tumor progression in bladder cancer,” Clinical Cancer Research, vol. 9, no. 15, pp. 5642–5651, 2003. View at Google Scholar · View at Scopus
  90. B. J. Park, S. J. Lee, J. I. Kim et al., “Frequent alteration of p63 expression in human primary bladder carcinomas,” Cancer Research, vol. 60, no. 13, pp. 3370–3374, 2000. View at Google Scholar · View at Scopus
  91. F. Koga, S. Kawakami, Y. Fujii et al., “Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder,” Clinical Cancer Research, vol. 9, no. 15, pp. 5501–5507, 2003. View at Google Scholar · View at Scopus
  92. O. Karni-Schmidt, M. Castillo-Martin, T. HuaiShen et al., “Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression,” American Journal of Pathology, vol. 178, no. 3, pp. 1350–1360, 2011. View at Publisher · View at Google Scholar
  93. M. M. Kroiss, A. K. Bosserhoff, T. Vogt et al., “Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas,” Melanoma Research, vol. 8, no. 6, pp. 504–509, 1998. View at Google Scholar · View at Scopus
  94. M. J. Kang, B. J. Park, D. S. Byun et al., “Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma,” Clinical Cancer Research, vol. 6, no. 5, pp. 1767–1771, 2000. View at Google Scholar · View at Scopus
  95. A. Tannapfel, S. Schmelzer, M. Benicke et al., “Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer,” Journal of Pathology, vol. 195, no. 2, pp. 163–170, 2001. View at Publisher · View at Google Scholar
  96. A. E. Vilgelm, S. M. Hong, M. K. Washington et al., “Characterization of Δnp73 expression and regulation in gastric and esophageal tumors,” Oncogene, vol. 29, no. 43, pp. 5861–5868, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. C. Cai, G. Y. Yang, V. Nie et al., “Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53,” Carcinogenesis, vol. 21, no. 4, pp. 683–689, 2000. View at Google Scholar · View at Scopus
  98. N. Masuda, H. Kato, T. Nakajima et al., “Synergistic decline in expressions of p73 and p21 with invasion in esophageal cancers,” Cancer Science, vol. 94, no. 7, pp. 612–617, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. J. N. Glickman, A. Yang, A. Shahsafaei, F. McKeon, and R. D. Odze, “Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders,” Human Pathology, vol. 32, no. 11, pp. 1157–1165, 2001. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Geddert, S. Kiel, H. J. Heep, H. E. Gabbert, and M. Sarbia, “The role of p63 and ΔNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis,” Human Pathology, vol. 34, no. 9, pp. 850–856, 2003. View at Publisher · View at Google Scholar
  101. M. Morita, H. Uramoto, S. Nakata et al., “Expression of DeltaNp63 in squamous cell carcinoma of the esophagus,” Anticancer Research, vol. 25, no. 5, pp. 3533–3539, 2005. View at Google Scholar · View at Scopus
  102. Y. Takahashi, T. Noguchi, S. Takeno, Y. Kimura, M. Okubo, and K. Kawahara, “Reduced expression of p63 has prognostic implications for patients with esophageal squamous cell carcinoma,” Oncology Reports, vol. 15, no. 2, pp. 323–328, 2006. View at Google Scholar · View at Scopus
  103. L. Y. Cao, Y. Yin, H. Li, Y. Jiang, and H. F. Zhang, “Expression and clinical significance of S100A2 and p63 in esophageal carcinoma,” World Journal of Gastroenterology, vol. 15, no. 33, pp. 4183–4188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. A. K. El-Naggar, S. Lai, G. L. Clayman et al., “P73 gene alterations and expression in primary oral and laryngeal squamous carcinomas,” Carcinogenesis, vol. 22, no. 5, pp. 729–735, 2001. View at Google Scholar · View at Scopus
  105. L. Faridoni-Laurens, J. Bosq, F. Janot et al., “P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63?” Oncogene, vol. 20, no. 38, pp. 5302–5312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Weber, U. Bellmann, F. Bootz, C. Wittekind, and A. Tannapfel, “Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck,” International Journal of Cancer, vol. 99, no. 1, pp. 22–28, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. K. Chen, S. S. Hsue, and L. M. Lin, “p73 expression for human buccal epithelial dysplasia and squamous cell carcinoma: does it correlate with nodal status of carcinoma and is there a relationship with malignant change of epithelial dysplasia?” Head and Neck, vol. 26, no. 11, pp. 945–952, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Lo Muzio, A. Santarelli, R. Caltabiano et al., “p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma,” Human Pathology, vol. 36, no. 2, pp. 187–194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. S. S. Liu, K. Y. K. Chan, A. N. Y. Cheung, X. Y. Liao, T. W. Leung, and H. Y. S. Ngan, “Expression of ΔNp73 and TAp73α independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma,” Clinical Cancer Research, vol. 12, no. 13, pp. 3922–3927, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. A. N. Cheung, K.-L. Tsun, K.-M. Ng et al., “P634A4 and TAp73 immunocytochemistry in liquid-based cervical cytology—potential biomarkers for diagnosis and progress prediction of cervical neoplasia,” Modern Pathology, vol. 23, no. 4, pp. 559–566, 2010. View at Publisher · View at Google Scholar
  111. T. Y. Wang, B. F. Chen, Y. C. Yang et al., “Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases,” Human Pathology, vol. 32, no. 5, pp. 479–486, 2001. View at Publisher · View at Google Scholar · View at Scopus
  112. Z. Lin, M. Liu, Z. Li, C. Kim, E. Lee, and I. Kim, “ΔNp63 protein expression in uterine cervical and endometrial cancers,” Journal of Cancer Research and Clinical Oncology, vol. 132, no. 12, pp. 811–816, 2006. View at Publisher · View at Google Scholar
  113. M. Mai, C. Qian, A. Yokomizo et al., “Loss of imprinting and allele switching of p73 in renal cell carcinoma,” Oncogene, vol. 17, no. 13, pp. 1739–1741, 1998. View at Google Scholar · View at Scopus
  114. B. Tuna, M. Unlu, G. Asian, M. Secil, and K. Yorukoglu, “Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies,” Analytical and Quantitative Cytology and Histology, vol. 31, no. 2, pp. 118–122, 2009. View at Google Scholar
  115. A. Ferru, S. Denis, J. Guilhot et al., “Expression of TAp73 and ΔNp73 isoform transcripts in thyroid tumours,” European Journal of Surgical Oncology, vol. 32, no. 2, pp. 228–230, 2006. View at Publisher · View at Google Scholar
  116. Y. Ito, H. Uramoto, K. Funa et al., “Delta Np73 expression in thyroid neoplasms originating from follicular cells,” Pathology, vol. 38, no. 3, pp. 205–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Malaguarnera, A. Mandarino, E. Mazzon et al., “The p53-homologue p63 may promote thyroid cancer progression,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 953–971, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. Y. Ito, T. Takeda, K. Wakasa, M. Tsujimoto, M. Sakon, and N. Matsuura, “Expression of p73 and p63 proteins in pancreatic adenocarcinoma: p73 overexpression is inversely correlated with biological aggressiveness,” International Journal of Molecular Medicine, vol. 8, no. 1, pp. 67–71, 2001. View at Google Scholar · View at Scopus
  119. M. G. House, M. Z. Guo, C. Iacobuzio-Donahue, and J. G. Herman, “Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas,” Carcinogenesis, vol. 24, no. 2, pp. 193–198, 2003. View at Publisher · View at Google Scholar · View at Scopus
  120. O. Basturk, F. Khanani, F. Sarkar, E. Levi, J. D. Cheng, and N. V. Adsay, “DeltaNp63 expression in pancreas and pancreatic neoplasia,” Modern Pathology, vol. 18, no. 9, pp. 1193–1198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. O. Petrenko, A. Zaika, and U. M. Moll, “ΔNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo,” Molecular and Cellular Biology, vol. 23, no. 16, pp. 5540–5555, 2003. View at Publisher · View at Google Scholar · View at Scopus
  122. T. Stiewe, S. Zimmermann, A. Frilling, H. Esche, and B. M. Pützer, “Transactivation-deficient δTA-p73 acts as an oncogene,” Cancer Research, vol. 62, no. 13, pp. 3598–3602, 2002. View at Google Scholar · View at Scopus
  123. H. Cam, H. Griesmann, M. Beitzinger et al., “p53 family members in myogenic differentiation and rhabdomyosarcoma development,” Cancer Cell, vol. 10, no. 4, pp. 281–293, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. I. Casciano, B. Banelli, M. Croce et al., “Role of methylation in the control of ΔNp73 expression in neuroblastoma,” Cell Death and Differentiation, vol. 9, no. 3, pp. 343–345, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Vilgelm, J. X. Wei, M. B. Piazuelo et al., “ΔNp73α regulates MDR1 expression by inhibiting p53 function,” Oncogene, vol. 27, no. 15, pp. 2170–2176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. H. Uramoto, K. Sugio, T. Oyama et al., “Expression of the p53 family in lung cancer,” Anticancer Research, vol. 26, no. 3, pp. 1785–1790, 2006. View at Google Scholar · View at Scopus
  127. M. Müller, T. Schilling, A. E. Sayan et al., “TAp73/ΔNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma,” Cell Death and Differentiation, vol. 12, no. 12, pp. 1564–1577, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. M. Wager, J. Guilhot, J. L. Blanc et al., “Prognostic value of increase in transcript levels of Tp73 ΔEx2-3 isoforms in low-grade glioma patients,” British Journal of Cancer, vol. 95, no. 8, pp. 1062–1069, 2006. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Meier, M. L. den Boer, J. P. P. Meijerink et al., “Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia,” Leukemia, vol. 20, no. 8, pp. 1377–1384, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. N. Concin, G. Hofstetter, A. Berger et al., “Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo,” Clinical Cancer Research, vol. 11, no. 23, pp. 8372–8383, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Beitzinger, L. Hofmann, C. Oswald et al., “p73 poses a barrier to malignant transformation by limiting anchorage-independent growth,” EMBO Journal, vol. 27, no. 5, pp. 792–803, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. P. G. Corn, S. J. Kuerbitz, M. M. van Noesel et al., “Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation,” Cancer Research, vol. 59, no. 14, pp. 3352–3356, 1999. View at Google Scholar · View at Scopus
  133. L. L. Shen, M. Toyota, Y. Kondo et al., “Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia,” Blood, vol. 101, no. 10, pp. 4131–4136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  134. G. Garcia-Manero, J. Daniel, T. L. Smith et al., “DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia,” Clinical Cancer Research, vol. 8, no. 7, pp. 2217–2224, 2002. View at Google Scholar · View at Scopus
  135. F. Vikhanskaya, W. H. Toh, I. Dulloo et al., “p73 supports cellular growth through c-Jun-dependent AP-1 transactivation,” Nature Cell Biology, vol. 9, no. 6, pp. 698–706, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. M. P. Tschan, T. J. Grob, U. R. Peters et al., “Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia,” Biochemical and Biophysical Research Communications, vol. 277, no. 1, pp. 62–65, 2000. View at Publisher · View at Google Scholar · View at Scopus
  137. K. Hagiwara, M. G. McMenamin, K. Miura, and C. C. Harris, “Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers,” Cancer Research, vol. 59, no. 17, pp. 4165–4169, 1999. View at Google Scholar · View at Scopus
  138. M. Sunahara, T. Shishikura, M. Takahashi et al., “Mutational analysis of p51A/TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer,” Oncogene, vol. 18, no. 25, pp. 3761–3765, 1999. View at Publisher · View at Google Scholar · View at Scopus
  139. K. Hibi, B. Trink, M. Patturajan et al., “AIS is an oncogene amplified in squamous cell carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 10, pp. 5462–5467, 2000. View at Publisher · View at Google Scholar · View at Scopus
  140. W. M. Keyes, M. Pecoraro, V. Aranda et al., “Δnp63α is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis,” Cell Stem Cell, vol. 8, no. 2, pp. 164–176, 2011. View at Publisher · View at Google Scholar
  141. A. A. Mills, B. Zheng, X. J. Wang, H. Vogel, D. R. Roop, and A. Bradley, “p63 is a p53 homologue required for limb and epidermal morphogenesis,” Nature, vol. 398, no. 6729, pp. 708–713, 1999. View at Publisher · View at Google Scholar · View at Scopus
  142. A. Yang, R. Schweitzer, D. Sun et al., “p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development,” Nature, vol. 398, no. 6729, pp. 714–718, 1999. View at Publisher · View at Google Scholar · View at Scopus
  143. E. R. Flores, S. Sengupta, J. B. Miller et al., “Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family,” Cancer Cell, vol. 7, no. 4, pp. 363–373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  144. M. I. Koster, S. Kim, A. A. Mills, F. J. DeMayo, and D. R. Roop, “p63 is the molecular switch for initiation of an epithelial stratification program,” Genes and Development, vol. 18, no. 2, pp. 126–131, 2004. View at Publisher · View at Google Scholar · View at Scopus
  145. R. A. Romano, K. Ortt, B. Birkaya, K. Smalley, and S. Sinha, “An active role of the ΔN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate,” PLoS ONE, vol. 4, no. 5, Article ID e5623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. T. Crook, J. M. Nicholls, L. Brooks, J. O'Nions, and M. J. Allday, “High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?” Oncogene, vol. 19, no. 30, pp. 3439–3444, 2000. View at Google Scholar · View at Scopus
  147. K. Yamaguchi, L. Wu, O. L. Caballero et al., “Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma,” International Journal of Cancer, vol. 86, no. 5, pp. 684–689, 2000. View at Google Scholar · View at Scopus
  148. E. Compérat, I. Bièche, D. Dargère et al., “p63 gene expression study and early bladder carcinogenesis,” Urology, vol. 70, no. 3, pp. 459–462, 2007. View at Publisher · View at Google Scholar
  149. S. Marchini, M. Marabese, E. Marrazzo et al., “ΔNp63 expression is associated with poor survival in ovarian cancer,” Annals of Oncology, vol. 19, no. 3, pp. 501–507, 2008. View at Publisher · View at Google Scholar
  150. C. E. Barbieri, L. J. Tang, K. A. Brown, and J. A. Pietenpol, “Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis,” Cancer Research, vol. 66, no. 15, pp. 7589–7597, 2006. View at Publisher · View at Google Scholar · View at Scopus
  151. M. Adorno, M. Cordenonsi, M. Montagner et al., “A Mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis,” Cell, vol. 137, no. 1, pp. 87–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  152. A. B. Truong, M. Kretz, T. W. Ridky, R. Kimmel, and P. A. Khavari, “p63 regulates proliferation and differentiation of developmentally mature keratinocytes,” Genes and Development, vol. 20, no. 22, pp. 3185–3197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  153. C. O. Leong, N. Vidnovic, M. P. DeYoung, D. Sgroi, and L. W. Ellisen, “The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1370–1380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  154. J. W. Rocco, C. O. Leong, N. Kuperwasser, M. P. DeYoung, and L. W. Ellisen, “p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis,” Cancer Cell, vol. 9, no. 1, pp. 45–56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  155. X. Guo, W. M. Keyes, C. Papazoglu et al., “TAp63 induces senescence and suppresses tumorigenesis in vivo,” Nature Cell Biology, vol. 11, no. 12, pp. 1451–1457, 2009. View at Google Scholar · View at Scopus
  156. S. Djelloul, M. Tarunina, K. Barnouin, A. Mackay, and P. S. Jat, “Differential protein expression, DNA binding and interaction with SV40 large tumour antigen implicate the p63-family of proteins in replicative senescence,” Oncogene, vol. 21, no. 7, pp. 981–989, 2002. View at Publisher · View at Google Scholar · View at Scopus
  157. D.-Y. Wang, C.-C. Cheng, M.-H. Kao, Y.-J. Hsueh, D. H. K. Ma, and J.-K. Chen, “Regulation of limbal keratinocyte proliferation and differentiation by TAp63 and ΔNp63 transcription factors,” Investigative Ophthalmology and Visual Science, vol. 46, no. 9, pp. 3102–3108, 2005. View at Publisher · View at Google Scholar
  158. W. Guo, S. Fan, Y. Jiang, J. Chen, Z. Li, and H. Niu, “The expression of p63 gene in human non-small cell lung cancer,” Zhongguo Fei Ai Za Zhi, vol. 7, no. 1, pp. 31–34, 2004. View at Google Scholar
  159. X. Su, D. Chakravarti, M. S. Cho et al., “TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs,” Nature, vol. 467, no. 7318, pp. 986–990, 2010. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Wang and W. S. El-Deiry, “p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints,” Cancer Research, vol. 66, no. 14, pp. 6982–6989, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. X. Chen, Y. Zheng, J. Zhu, J. Jiang, and J. Wang, “p73 is transcriptionally regulated by DNA damage, p53, and p73,” Oncogene, vol. 20, no. 6, pp. 769–774, 2001. View at Publisher · View at Google Scholar · View at Scopus
  162. J. Wang, Y. X. Liu, M. P. Hande, A. C. Wong, Y. J. Jin, and Y. Yin, “TAp73 is a downstream target of p53 in controlling the cellular defense against stress,” Journal of Biological Chemistry, vol. 282, no. 40, pp. 29152–29162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  163. J. Johnson, J. Lagowski, S. Lawson, Y. Liu, and M. Kulesz-Martin, “p73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis,” Oncogene, vol. 27, no. 19, pp. 2780–2787, 2008. View at Publisher · View at Google Scholar · View at Scopus
  164. S. Strano, G. Fontemaggi, A. Costanzo et al., “Physical interaction with human tumor-derived p53 mutants inhibits p63 activities,” Journal of Biological Chemistry, vol. 277, no. 21, pp. 18817–18826, 2002. View at Publisher · View at Google Scholar · View at Scopus
  165. C. J. Di Como, C. Gaiddon, and C. Prives, “p73 Function is inhibited by tumor-derived p53 mutants in mammalian cells,” Molecular and Cellular Biology, vol. 19, no. 2, pp. 1438–1449, 1999. View at Google Scholar · View at Scopus
  166. C. Gaiddon, M. Lokshin, J. Ahn, T. Zhang, and C. Prives, “A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain,” Molecular and Cellular Biology, vol. 21, no. 5, pp. 1874–1887, 2001. View at Publisher · View at Google Scholar · View at Scopus
  167. C. D. Pozniak, S. Radinovic, A. Yang, F. McKeon, D. R. Kaplan, and F. D. Miller, “An anti-apoptotic role for the p53 family member, p73, during developmental neuron death,” Science, vol. 289, no. 5477, pp. 304–306, 2000. View at Publisher · View at Google Scholar · View at Scopus
  168. G. Liu, S. Nozell, H. Xiao, and X. Chen, “ΔNp73β is active in transactivation and growth suppression,” Molecular and Cellular Biology, vol. 24, no. 2, pp. 487–501, 2004. View at Publisher · View at Google Scholar · View at Scopus
  169. E. R. Flores, K. Y. Tsai, D. Crowley et al., “p63 and p73 are required for p53-dependent apoptosis in response to DNA damage,” Nature, vol. 416, no. 6880, pp. 560–564, 2002. View at Publisher · View at Google Scholar · View at Scopus
  170. R. Cui, T. T. Nguyen, J. H. Taube, S. A. Stratton, M. H. Feuerman, and M. C. Barton, “Family members p53 and p73 act together in chromatin modification and direct repression of α-fetoprotein transcription,” Journal of Biological Chemistry, vol. 280, no. 47, pp. 39152–39160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  171. A. Yang, Z. Zhu, A. Kettenbach et al., “Genome-wide mapping indicates that p73 and p63 Co-occupy target sites and have similar DNA-binding profiles in vivo,” PLoS ONE, vol. 5, no. 7, Article ID e11572, 2010. View at Publisher · View at Google Scholar · View at Scopus